Results 81 to 90 of about 13,099 (221)

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2010
Introduction Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia.
Ćojbašić Irena, Mačukanović-Golubović Lana   +1 more
doaj   +1 more source

Excellent Survival Following Low‐Intensity Approaches Prior to Allo‐HSCT in Ph+ ALL: A Comprehensive Meta‐Analysis

Advances in Hematology, Volume 2026, Issue 1, 2026.
Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) is a therapeutic challenge, particularly for elderly patients and those with comorbidities. While traditional intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is highly effective, therapy‐related toxicity and mortality is a ...
Lacey S. Williams, Wenners Ballard III, Deniz Ozisik, Charles Scott Dorris, Kepher Makambi, Scott Rowley, Kieron Dunleavy, John DiPersio, Alaa Ali, Kalyani Sen   +9 more
wiley   +1 more source

Multifaceted Small Molecules as Enzyme Modulators: Cases of Drug Discovery/Repurposing Illustrating Nature′s Pragmatism

BioMed Research International, Volume 2026, Issue 1, 2026.
The cross‐reactivity of substrates, modulators with other enzymes significantly reduces/prevents our ability to design such highly specific, that is, “one warhead–one target”, modulators. On the other hand, the potential “impasse” fuels repurposing of already developed drugs.
Monika I. Konaklieva, Balbina J. Plotkin, Nahit Gencer   +2 more
wiley   +1 more source

Interferon-alpha-Treated Patients with Chronic Myelogenous Leukemia Show BCR/ABL-Positive Peripheral Blood Progenitor Cells Surviving Long-Term Culture

Folia Biologica, 2000
Several groups have shown that Ph-progenitors reappear in LTC of CML bone marrow or PBMNC when the cell preparations were derived from newly diagnosed Ph-positive patients or after induction chemotherapy. We have tested the hypothesis whether LTC may further decrease CML progenitors if the cells to be cultured were from IFN-treated
B, Schultheis, B, Heissig, G, Pasternak, S, Hörner, R, Hehlmann   +4 more
openaire   +2 more sources

MXene‐Based Electrochemiluminescence (ECL) Biosensors: A Review on Analyte Detection and Diagnostic Applications

MedComm – Biomaterials and Applications, Volume 4, Issue 4, December 2025.
This review highlights recent advances in MXene‐based electrochemiluminescence (ECL) biosensors, showcasing their exceptional sensitivity and versatility in detecting biomolecules, pathogens, and environmental pollutants. The integration of MXenes significantly enhances ECL signal amplification, paving the way for next‐generation diagnostic and ...
Kai Zhang
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms

Advanced Science, Volume 12, Issue 37, October 6, 2025.
Cardiovascular disease (CVD) and cancer are leading causes of death worldwide, with overlapping risk factors and pathophysiological mechanisms. This review explores shared pathways, including metabolic dysregulation, chronic inflammation, and gut microbiome alterations, highlighting dual‐benefit strategies such as lifestyle modifications and repurposed
Shihan Xiang, Yujie Shan, Shihong Xu, Jing Wang, Meng Luo, Jiaojiao Zhou, Qishan Chen   +6 more
wiley   +1 more source

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa [PDF]

, 2012
The T315I BCR-ABL mutation in chronic myelogenous leukemia (CML) patients is responsible for up to 20% of all clinically observed resistance. This mutation confers resistance not only to imatinib, but also to second-generation BCR-ABL tyrosine kinases ...
Matsuo, Emi, Kawaguchi, Yasuhisa, Tsushima, Hideki, Kamihira, Shimeru, Tomonaga, Masao, Miyazaki, Yasushi, Hata, Tomoko, Imaizumi, Yoshitaka, Fukushima, Takuya, Itonaga, Hidehiro, Doi, Yuko, Mori, Sayaka, Imanishi, Daisuke   +12 more
core   +1 more source

The Anti‐Leukemic Potential of Curcumin in Chronic Myeloid Leukemia: A Systematic Review of In Vitro Studies

Food Science &Nutrition, Volume 13, Issue 9, September 2025.
Curcumin suppresses chronic myeloid leukemia progression through multiple molecular pathways. It inhibits BCR‐ABL1, modulates miR‐21, PKCα, and PTEN, activates DR4/DR5, blocks G2/M cell cycle progression, and inhibits HDAC. These actions collectively promote apoptosis, enhance tumor suppressor expression, and reduce leukemic cell proliferation ...
Hossein Bahari, Zeinab Salim, Leila Kardanpour, Hosein Kouchaki, Fatemeh Shoja, Iman Rahnama, Arezoo Faridzadeh, Maryam Ranjbar Zahedani   +7 more
wiley   +1 more source

A Case of Hepatocellular Carcinoma after Treatment for Chronic Myeloid Leukemia in a Patient without Liver Disease

Case Reports in Oncology
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the reciprocal translocation of chromosomes 9 and 22, which leads to a chimeric gene product known as BCR-ABL.
Darshankumar M. Raval, Ricardo J. Pagán, Shayan Butt, Libardo Rueda Prada   +3 more
doaj   +1 more source